Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 in Sepsis Patients
NCT02797431Phase 2Terminated
- Sponsor
- CHU de Limoges
- Start
- Jan 2016
- Primary completion
- Mar 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant human interleukin-7 in sepsis and septic shock (3 arms), sponsored by CHU de Limoges. Primary endpoints: White blood count, Lymphocyte percentage and 2 more. Started Jan 2016; status: terminated.
02
Drugs
recombinant human interleukin-7
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT02797431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797431.